Mary Tagliaferri

Mary Tagliaferri is the current Senior Vice President and Executive Clinical Fellow at Nektar Therapeutics. Mary has also previously served as Chief Medical Officer for Kanglaite and as a Consultant-Project Team Lead for InterMune.

Mary has been instrumental in Nektar's success, playing a key role in the company's clinical development, FDA regulatory affairs, public relations, financing, intellectual property protection and business development. Mary has also been responsible for all clinical development, clinical operations, medical monitoring, drug safety and FDA regulatory affairs for Nektar.

Mary has a wealth of experience in the pharmaceutical industry, having also served as Chief Medical Officer for Kanglaite and as a Consultant-Project Team Lead for InterMune. In their role at InterMune, they led the Expanded Access Program (EAP) with Pirfenidone for Idiopathic Pulmonary Fibrosis. The EAP was offered at 92 clinical sites in the US and over 1,800 patients were enrolled in the pre-approval period.

Mary is a highly accomplished pharmaceutical executive with a proven track record of success in leading companies to success. Mary is a strategic thinker with a deep understanding of the pharmaceutical industry and the drug development process. Her experience and expertise are invaluable assets to Nektar Therapeutics.

Mary Tagliaferri is an MD who graduated from the University of California, San Francisco. Mary also holds a LAc from the American College of Traditional Chinese Medicine and a BS from Cornell University.

Mary Tagliaferri reports to Howard Robin, President & CEO. Mary Tagliaferri works with Jennifer Ruddock - SVP, Investor Relations & Corporate Affairs, Brian L. Kotzin - Chief Medical Officer, and Mark A. Wilson - SVP, General Counsel.